{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:46:43Z","timestamp":1789213603690,"version":"build-2803163510"},"reference-count":33,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"TUBITAK KAMAG 1007 project 113G100"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The EGFR pathway is activated by ligand binding, and EGFR overexpression is linked to malignancies like colorectal and head and neck cancer. This pathway is targeted by monoclonal antibodies such as Cetuximab; however, drug resistance can arise, frequently because of EGFR gene alterations like mutation, particularly in domain III, which inhibits Cetuximab binding. EGFR and MEGFR (R497K mutated EGFR) plasmids were transfected into Chinese hamster ovary (CHO) cells, which do not express EGFR. Real-time PCR was performed using probes that were specifically developed for the R497K mutation. Furthermore, Cetuximab binding to EGFR and MEGFR was examined using molecular modeling. According to molecular modeling, the R497K mutation modifies the domain III structure, which lowers the binding affinity of Cetuximab. Curiously, Cetuximab also showed binding to MEGFR\u2019s domain IV. Real-time PCR showed that the probes specifically identified MEGFR in transfected CHO cells. The R497K mutation may result in treatment resistance by decreasing Cetuximab binding or increasing competitive ligand binding. Therefore, for individualized treatment, it is essential to find EGFR mutations in patient tumor samples. The R497K mutation may be successfully detected by the designed oligonucleotide probes, allowing for the early identification of potential resistance and directing the development of suitable treatment strategies.<\/jats:p>","DOI":"10.3390\/ijms26083594","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T03:45:23Z","timestamp":1744343123000},"page":"3594","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Experimental System Design and Modelling of EGFR Extracellular Domain and Its Mutant Binding to Antibody Interacting Partner"],"prefix":"10.3390","volume":"26","author":[{"given":"Feyzanur","family":"Erdemir","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, Institute of Natural Sciences, Acibadem Mehmet Ali Aydinlar University, Istanbul 34752, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertan Koray","family":"Balcioglu","sequence":"additional","affiliation":[{"name":"Medical Biotechnology Unit, Life Sciences, TUBITAK Marmara Research Center, Gebze 41470, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1833-8603","authenticated-orcid":false,"given":"Tugba Arzu","family":"Ozal Ildeniz","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Acibadem Mehmet Ali Aydinlar University, Istanbul 34752, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozge","family":"Can","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Acibadem Mehmet Ali Aydinlar University, Istanbul 34752, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2021, February 12). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"526963","DOI":"10.1155\/2009\/526963","article-title":"Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer","volume":"2009","author":"Flynn","year":"2009","journal-title":"J. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Gao, L.B., Zhou, B., Zhang, L., Wei, Y.-S., Wang, Y.-Y., Liang, W.-B., Lv, M.-L., Pan, X.-M., Chen, Y., and Rao, C.L. (2008). R497K polymorphism in epidermal growth factor receptor gene is associated with the risk of acute coronary syndrome. BMC Med. Genet., 9.","DOI":"10.1186\/1471-2350-9-74"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0091270010395940","article-title":"Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: Development of cetuximab and panitumumab","volume":"52","author":"You","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"ref_6","first-page":"E3595","article-title":"Mechanism for activation of mutated epidermal growth factor receptors in lung cancer","volume":"110","author":"Brewer","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","article-title":"Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study","volume":"6","author":"Moroni","year":"2005","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.3748\/wjg.v22.i28.6345","article-title":"Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer","volume":"22","author":"Sforza","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ctrv.2010.07.008","article-title":"All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer","volume":"37","author":"Linardou","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"ref_10","first-page":"312102","article-title":"A Meta-Analysis on the Relations between EGFR R521K Polymorphism and Risk of Cancer","volume":"2014","author":"Wang","year":"2014","journal-title":"Int. J. Genom."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00432-008-0464-5","article-title":"EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer","volume":"135","author":"Sasaki","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.23958\/ijirms\/vol01-i02\/01","article-title":"Role of Molecular Modelling in Drug Design","volume":"1","author":"Prabha","year":"2016","journal-title":"Int. J. Innov. Res. Med. Sci."},{"key":"ref_13","first-page":"169","article-title":"Force fields and molecular dynamics simulations. \u00c9cole Th\u00e9matique de La Soci\u00e9t\u00e9 Fran\u00e7aise de La Neutronique","volume":"12","year":"2011","journal-title":"EDP Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1021\/cr040426m","article-title":"Molecular dynamics: Survey of methods for simulating the activity of proteins","volume":"106","author":"Adcock","year":"2006","journal-title":"Chem. Rev."},{"key":"ref_15","first-page":"850","article-title":"1.27 Computational Kinetics: Application to Nuclear Materials","volume":"1","author":"Perron","year":"2020","journal-title":"Compr. Nucl. Mater."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Salmaso, V., and Moro, S. (2018). Bridging Molecular Docking to Molecular Dynamics in Exploring Ligand-Protein Recognition Process: An Overview. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00923"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: A powerful approach for structure-based drug discovery","volume":"7","author":"Meng","year":"2011","journal-title":"Curr. Comput. Aided-Drug Des."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/154214090964762","article-title":"Review of: Molecular Modelling for Beginners","volume":"442","author":"Liebman","year":"2005","journal-title":"Mol. Cryst. Liq. Cryst."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: Visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pierce, B.G., Hourai, Y., and Weng, Z. (2011). Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024657"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/prot.10389","article-title":"ZDOCK: An initial-stage protein-docking algorithm","volume":"52","author":"Chen","year":"2003","journal-title":"Proteins Struct Funct. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1158\/0008-5472.CAN-16-0754","article-title":"Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism","volume":"77","author":"Braig","year":"2017","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1126\/science.291.5512.2370","article-title":"Glycosylation and the immune system","volume":"291","author":"Rudd","year":"2001","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1525-1578(10)60569-7","article-title":"Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas","volume":"7","author":"Pan","year":"2005","journal-title":"J. Mol. Diagn."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.lungcan.2007.10.011","article-title":"Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer","volume":"60","author":"Zhang","year":"2008","journal-title":"Lung Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/JTO.0000000000000041","article-title":"Clinical characteristics and treatment outcomes of lung adenocarcinomas with discrepant EGFR mutation testing results derived from PCR-direct sequencing and real-time PCR-based assays","volume":"9","author":"Chiu","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Angulo, B., Conde, E., Su\u00e1rez-Gauthier, A., Plaza, C., Mart\u00ednez, R., Redondo, P., Izquierdo, E., Rubio-Viqueira, B., Paz-Ares, L., and Hidalgo, M. (2012). A comparison of EGFR mutation testing methods in lung carcinoma: Direct sequencing, real-TIME PCR and immunohistochemistry. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043842"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1515\/cclm-2016-0851","article-title":"Assessment of real-time PCR method for detection of EGFR mutation using both supernatant and cell pellet of malignant pleural effusion samples from non-small-cell lung cancer patients","volume":"55","author":"Shin","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1101\/gr.6.10.986","article-title":"Real-time quantitative PCR","volume":"6","author":"Heid","year":"1996","journal-title":"Genome Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00428-008-0665-y","article-title":"KRAS mutation testing for predicting response to anti-EGFR therapy for colo-rectal carcinoma: Proposal for a European quality assurance program","volume":"453","author":"Jung","year":"2008","journal-title":"Virchows Arch."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2353\/jmoldx.2010.090188","article-title":"Comparison of sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations","volume":"12","author":"Tsiatis","year":"2010","journal-title":"J. Mol. Diagn."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/8\/3594\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:12:34Z","timestamp":1760029954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/8\/3594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["ijms26083594"],"URL":"https:\/\/doi.org\/10.3390\/ijms26083594","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}